Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders - a comprehensive systematic review and meta-analysis

Research output: Contribution to journalReviewResearchpeer-review

  1. Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A phenome-wide association and Mendelian Randomisation study of polygenic risk for depression in UK Biobank

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Sex differences in trauma exposure and symptomatology in trauma-affected refugees

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Detection of illness worry in the general population: A specific item on illness rumination improves the Whiteley Index

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effectiveness of cognitive remediation in the ultra-high risk state for psychosis

    Research output: Contribution to journalLetterResearchpeer-review

  5. The Duffy-null genotype and risk of infection

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Antipsychotic effects of immunomodulating drugs have been suggested; however, a thorough, comprehensive meta-analysis on the effect and safety of anti-inflammatory add-on treatment on psychotic disorders is lacking.

METHOD: Multiple databases were searched up until February 2020. Only double-blinded, randomized, placebo-controlled clinical trials (RCTs) were included. Primary outcomes were change in total psychopathology and adverse events. Secondary outcomes included amongst others, positive and negative symptoms, general psychopathology and cognitive domains. We performed random-effects meta-analyses estimating mean differences (MD) and standardized mean differences (SMD) for effect sizes.

RESULTS: Seventy RCTs (N=4104) were included, investigating either primarily anti-inflammatory drugs, i.e. drug developed for immunomodulation, such as NSAIDs, minocycline and monoclonal antibodies (k=15), or drugs with potential anti-inflammatory properties (k=55), e.g. neurosteroids, N-acetyl cysteine, estrogens, fatty acids, statins, and glitazones. Antipsychotics plus anti-inflammatory treatment, compared to antipsychotics plus placebo, was associated with a PANSS scale MD improvement of -4.57 (95%CI= -5.93 to -3.20) points, corresponding to a SMD effect size of -0.29 (95%CI= -0.40 to -0.19). Trials on schizophrenia (MD= -6.80; 95%CI, -9.08 to -4.52) showed greater improvement (p<0.01) than trials also including other psychotic disorders. However, primarily anti-inflammatory drugs (MD=4.00; 95%CI= -7.19 to -0.80) was not superior (p=0.69) to potential anti-inflammatory drugs (MD=4.71; 95%CI= -6.26 to -3.17). Furthermore, meta regression found that smaller studies showed significantly larger effect sizes than the larger studies (p=0.0085), and only 2 studies had low risk of bias on all domains. Small but significant effects were found on negative symptoms (MD= -1.29), positive symptoms (MD= -0.53), general psychopathology (MD= -1.50) and working memory (SMD= 0.21). No differences were found regarding adverse events, but only 26 studies reported hereon.

CONCLUSIONS: Anti-inflammatory add-on treatment to antipsychotics showed improvement of psychotic disorders; however, no superiority was found in primarily anti-inflammatory drugs raising the question of the mechanism behind the effect, and treatment effect might be overestimated due to the large number of small studies.

Original languageEnglish
JournalBrain, Behavior, and Immunity
Publication statusE-pub ahead of print - 2 Sep 2020

ID: 60906265